1,800,000 Shares in GH Research PLC $GHRS Acquired by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC purchased a new position in GH Research PLC (NASDAQ:GHRS) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,800,000 shares of the company’s stock, valued at approximately $22,860,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Barclays PLC grew its stake in shares of GH Research by 63.4% in the 4th quarter. Barclays PLC now owns 2,118 shares of the company’s stock worth $27,000 after buying an additional 822 shares during the last quarter. Osaic Holdings Inc. grew its stake in shares of GH Research by 63.6% in the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after buying an additional 2,400 shares during the last quarter. Jefferies Financial Group Inc. grew its stake in shares of GH Research by 0.4% in the 4th quarter. Jefferies Financial Group Inc. now owns 712,300 shares of the company’s stock worth $9,046,000 after buying an additional 2,988 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of GH Research in the 4th quarter worth approximately $38,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of GH Research in the 2nd quarter worth approximately $79,000. Hedge funds and other institutional investors own 56.90% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on the company. Cantor Fitzgerald increased their target price on GH Research from $25.00 to $35.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Citizens Jmp cut their target price on GH Research from $42.00 to $39.00 and set a “market outperform” rating on the stock in a research note on Friday, May 15th. Citigroup reiterated an “outperform” rating on shares of GH Research in a research note on Friday, May 15th. Needham & Company LLC increased their target price on GH Research from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Finally, Guggenheim set a $34.00 target price on GH Research and gave the company a “buy” rating in a research note on Tuesday, March 10th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $40.38.

GH Research Trading Down 1.9%

Shares of GHRS opened at $19.98 on Wednesday. The business’s fifty day simple moving average is $20.43 and its two-hundred day simple moving average is $16.80. GH Research PLC has a 12 month low of $11.32 and a 12 month high of $25.94. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -21.72 and a beta of 1.31.

GH Research (NASDAQ:GHRS) last issued its earnings results on Thursday, May 14th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.04). As a group, research analysts forecast that GH Research PLC will post -1.46 EPS for the current year.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.